Stock Events

Stock Events

Ondine Biomedical 

$0.2200
6
-$0.03-12% Tuesday 15:38

Statistics

Day High
0.22
Day Low
0.22
52W High
0.25
52W Low
0.14
Volume
5,000
Avg. Volume
2,650
Mkt Cap
97.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

29SepExpected
Q1 2024
Q2 2024
Q4 2024
Q1 2025
Q2 2025
Q4 2025
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-931.43%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
1.46MRevenue
-13.56MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow OBIMF. It's not an investment recommendation.
Rio Tinto
4
RIO.LSE
Amazon
3
AMZN
Alphabet
3
GOOG
Alphabet
3
GOOGL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbvie
ABBV
Mkt Cap466.45B
AbbVie operates in the pharmaceuticals sector, focusing on immunology and oncology, areas that overlap with Ondine's antimicrobial photodynamic therapy.
Johnson & Johnson
JNJ
Mkt Cap650.65B
Johnson & Johnson, through its pharmaceutical division, competes in developing treatments that could potentially overlap with Ondine's infection prevention solutions.
Pfizer
PFE
Mkt Cap157.65B
Pfizer is involved in the development and commercialization of vaccines and drugs, including those for infections, directly competing with Ondine's focus.
Merck
MRK
Mkt Cap362.35B
Merck is known for its strong focus on infectious diseases, directly competing with Ondine's antimicrobial therapies.
Gilead Sciences
GILD
Mkt Cap186.13B
Gilead Sciences focuses on antiviral drugs, which could be seen as alternative treatments to Ondine's photodynamic therapies for infections.
Bristol-Myers Squibb
BMY
Mkt Cap128.81B
Bristol Myers Squibb engages in biopharmaceuticals, competing in the space of innovative treatments for various diseases, including those targeted by Ondine.
AMGEN
AMGN
Mkt Cap208.49B
Amgen focuses on human therapeutics, with a broad portfolio that could compete with Ondine's therapies in certain therapeutic areas.
Novartis
NVS
Mkt Cap266.8B
Novartis focuses on a wide range of healthcare areas, including treatments for diseases that Ondine's technology targets.
Astrazeneca
AZN
Mkt Cap257.57B
AstraZeneca operates in several therapeutic areas, including infections, directly competing with Ondine's infection prevention and treatment technologies.
Sanofi
SNY
Mkt Cap101.79B
Sanofi focuses on healthcare solutions across a broad range of areas, including infectious diseases, making it a competitor to Ondine's technologies.

About

Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-associated pneumonia, burns and other indications. Ondine Biomedical Inc. was incorporated in 1996 and is headquartered in Vancouver, Canada.
Show more...
CEO
Country
Canada
ISIN
CA68234M2058
WKN
000A3C813

Listings

F
DE
VF5.F
LSE
GB
OBI.LSE
OTC Link
US
OBIMF

0 Comments

Share your thoughts

FAQ

What is Ondine Biomedical stock price today?▼
The current price of OBIMF is $0.22 USD — it has decreased by -12% in the past 24 hours. Watch Ondine Biomedical stock price performance more closely on the chart.
What is Ondine Biomedical stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Ondine Biomedical stocks are traded under the ticker OBIMF.
What is Ondine Biomedical market cap?▼
Today Ondine Biomedical has the market capitalization of 97.56M
When is the next Ondine Biomedical earnings date?▼
Ondine Biomedical is going to release the next earnings report on September 29, 2026.
What is Ondine Biomedical revenue for the last year?▼
Ondine Biomedical revenue for the last year amounts to 1.46M USD.
What is Ondine Biomedical net income for the last year?▼
OBIMF net income for the last year is -13.56M USD.
In which sector is Ondine Biomedical located?▼
Ondine Biomedical operates in the Other sector.
When did Ondine Biomedical complete a stock split?▼
Ondine Biomedical has not had any recent stock splits.